Αρχική World News Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients... World News Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC Από Ogkologos - 17 Μαρτίου, 2026 430 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... 22 Μαρτίου, 2018 ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... 21 Ιουλίου, 2025 Cancer in My Community: Improving Access to Palliative Care in Indonesia 13 Ιανουαρίου, 2022 Conducting Phase I Clinical Trials During the COVID-19 Pandemic 5 Αυγούστου, 2020 Φόρτωση περισσοτέρων HOT NEWS We’re asking scientists to tackle 9 of the toughest challenges in... 5 Tips for Managing Financial Stress During Cancer 运动对肺癌患者的益处 ESMO Breast Cancer Congress 2023